Early access
Sign in
Taking people in SpainPhase 4

Insulin resistance in the heart muscle of people with type 2 diabetes

Uses heart scans to study how insulin resistance affects the heart in type 2 diabetes.

Key facts

Who runs it
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Where
Barcelona, SpainSee the site
Registry title
Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i
Status
Recruiting
Phase
Phase 4
People taking part
60 people, planned
Started
15 Oct 2026
Expected to end
30 Sept 2027
Type of study
Interventional
Record updated
19 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes, a body mass index (BMI) around 30 kg/m2 and an HbA1c between 7-9% (53–75 mmol/mol), who do not smoke or drink alcohol.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Type 2 diabetes (DM2) with HbA1c between 7-9% (53–75 mmol/mol).
Earlier treatment
Must not be treated with SGLT2 inhibitors or GLP-1 analogs.
Biomarker or test result
HbA1c between 7-9% (53–75 mmol/mol).

Main reasons for not taking part

  • Previous cardiovascular disease events
  • Liver or kidney complications
  • Claustrophobia to PET/CT and SPECT scans
  • Treatment with SGLT2 inhibitors or GLP-1 analogs
  • Smoking or alcohol use

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • BMI around 30 kg/m2
  • DM2
  • no-smoking; no-alcohol
  • HbA1c between 7-9%

Who cannot take part

  • previous CVD events
  • treatment with SGLT2 inhibitors or GLP-1 analogs
  • hepatic and kidney complications
  • claustrophobia to PET/CT and SPECT

Where in Spain

  • Hospital Universitari Vall d'HebronBarcelona, SpainTaking people

About the trial

What the trial wants to find out

To determine by means of 18F-FDG PET/CT and 99mTc-Tetrofosmin SPECT whether myocardial IR affects cardiac function and coronary flow and is therefore a risk factor for cardiovascular events and diabetic cardiomyopathy in DM2 patients with myocardial IR phenotype

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i
Plain-language title
Insulin resistance in the heart muscle of people with type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
19 June 2026